This week, biopharmaceutical Company
XORTX Therapeutics Inc. (CSE: XRX, OTCQB: XRTXF, Forum) highlighted several recent milestones it had achieved among its three key programs, such as: Its XRx-008 program for Autosomal Dominant Polycystic Kidney Disease, XRx-101 for COVID-19 coronavirus infection and XRx-221 for Type 2 Diabetic Nephropathy.
To find out more about this news, click
here.
XORTX recently appointed
Dr. Anjay Rastogi MD PhD to its clinical advisory board. He is a Professor and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, where he is also the director of the CORE PKD (Polycystic Kidney Disease) Center. He has clinical experience treating patients with Autosomal Dominant Polycystic Kidney Disease.
FULL DISCLOSURE: XORTX Therapeutics Inc. is a paid client of Stockhouse Publishing.